Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trial
BioPharma Reporter
MAY 10, 2022
Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.
Let's personalize your content